System1 claims it ‘hasn’t scratched the surface’ with bumper results
Ad testing firm System1 pointed to the 260 clients it had won in the past year as being the driving force behind growth in profit and revenve.
Topps Tiles’ sales continue to fall as homeowners steer clear of ‘big ticket’ DIY
The London-listed Topps Tiles Group has seen sales drop year-on-year as it says demand for big-ticket home projects remains low amid a "challenging" macroenvironment.
Fintel pays Abrdn £14.6m for Threesixty amid acquisition spree
SimplyBiz parent company Fintel has completed its purchase of Threesixty Services from asset manager Abrdn in the AIM-listed firm's latest acquisition.
This government is out of ideas, out of energy, and deserves to be out of office
Our verdict on the General Election: this Conservative party deserves a spell on the sidelines
South Yorkshire firm Intelliam AI floats on the Aquis Stock Exchange
South Yorkshire AI firm Intelliam AI made its stock market debut this morning, floating on the Aquis stock exchange in a move that valued the firm at nearly £18m.
Baltics Classifieds Group hikes dividend as profit rises by a third
Justinas Šimkus, CEO of Baltic Classifieds Group, said "2024 marked another year of solid financial, operational and strategic execution."
Equals: Payments fintech notches jump in revenue ahead of potential takeover
AIM-listed fintech Equals has notched a jump in revenue for the first half of 2024, helped by "strong growth" in its solutions platform, as it readies for a possible takeover offer.
Cairn Homes: Surge in first time buyers drives record revenue
Irish housebuilder Cairn Homes has seen its revenue hit record levels due to a surge in demand among first time buyers.
Hawksmoor restaurant chain reportedly looking for buyer
Since 2013, the chain has been majority-owned by private equity firm Graphite Capital, which, according to the Financial Times, has instructed the US investment bank Stephens to run a sales process.
GSK to pay Curevac £1.2bn for full rights to develop and commercialise mRNA vaccines
GSK will assume full control of developing and manufacturing the candidate vaccines and will have worldwide rights to commercialise them.